Mizuho Securities analyst Mara Goldstein maintained a Buy rating on Nektar Therapeutics (NKTR – Research Report) today and set a price target of $35.00. The company’s shares closed last Friday at $10.63, close to its 52-week low of $9.31.
According to TipRanks.com, Goldstein is a 4-star analyst with an average return of 5.4% and a 37.2% success rate. Goldstein covers the Healthcare sector, focusing on stocks such as Iovance Biotherapeutics, Neoleukin Therapeutics, and Corvus Pharmaceuticals.
Nektar Therapeutics has an analyst consensus of Moderate Buy, with a price target consensus of $23.00, which is an 116.4% upside from current levels. In a report issued on March 9, Oppenheimer also upgraded the stock to Buy with a $21.00 price target.
Nektar Therapeutics’ market cap is currently $1.98B and has a P/E ratio of -3.72.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
Nektar Therapeutics is a biopharmaceutical company, which engages in applying technology platforms to develop novel drug candidates. The company focuses on the therapies for cancer, autoimmune disease, and chronic pain. It operates through the United States and Europe geographical segments. The company was founded in 1990 and is headquartered in San Francisco, CA.
Read More on NKTR: